Doha – Sharikat Mubasher: Kardium Inc., the Canadian medical technology company behind the Globe Pulsed Field System for treating atrial fibrillation (AF), raised $250 million in an oversubscribed financing round.
The round drew support from new investors including Qatar Investment Authority (QIA), Janus Henderson Investors, MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital, alongside existing backers such as T. Rowe Price and Durable Capital Partners.
The funding will support the commercial rollout of the Globe System, expand manufacturing capacity, and scale clinical and commercial teams. CEO Kevin Chaplin described the raise as "transformational," positioning Kardium to bring its innovative system to patients worldwide.
The Globe System, which features a 122-electrode catheter and advanced software for pulsed field ablation, recently posted strong clinical results at the 2025 Heart Rhythm Society meeting. Data from the PULSAR trial showed 78% freedom from arrhythmia after one year and zero device-related safety events in paroxysmal AF patients.
Kardium also plans to use the funds for regulatory approvals and further clinical research to broaden the system’s applications.
